PsychoactiveMap

Johns Hopkins University psychedelic research trials

Data as of 31 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.

Johns Hopkins University is listed with 6 registered studies counted here, in Baltimore, United States. By compound: 3 psilocybin and 3 ketamine. By registry status: 1 recruiting, 1 not yet recruiting, 1 enrolling by invitation, 2 completed and 1 withdrawn. By phase: 2 phase 1, 2 phase 2, 1 phase 3 and 1 phase 4. Reported start years run from 2018 (earliest) to 2027 (latest).

Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.

Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.

At a glance

By compound

Compound hubStudies
Psilocybin3
Ketamine3

By registry status

StatusStudiesShare
Recruiting117%
Not yet recruiting117%
Enrolling by invitation117%
Completed233%
Withdrawn117%

By phase

PhaseStudiesShare
Phase 1233%
Phase 2233%
Phase 3117%
Phase 4117%

Registered studies

All counted studies, newest start first. Dates may be estimated, including future dates; a listed date does not confirm that a study started. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.

Title as registeredRegistry IDStatusPhaseRegistry datesCompound
Inpatient Buprenorphine Induction With Psilocybin for Opioid Use DisorderNCT06005662WithdrawnPhase 2Source start: 2027-04 (estimated)
Saved start 2027-04-01 differs from reported 2027-04; the saved day is not established by this observation.
Source date details

Start: 2027-04 (precision: month; source type: ESTIMATED; estimated)

Primary completion: 2028-07 (precision: month; source type: ESTIMATED; estimated)

Study completion: 2028-07 (precision: month; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:16.980Z; registry revision: 2026-02-23 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Psilocybin
The Impact of Dose on the Impairing, Intoxicating, and Abuse-Related Effects of PsilocybinNCT07877987Not yet recruitingPhase 1Source start: 2027-03-01 (estimated)
Source date details

Start: 2027-03-01 (precision: day; source type: ESTIMATED; estimated)

Primary completion: 2030-06-30 (precision: day; source type: ESTIMATED; estimated)

Study completion: 2030-06-30 (precision: day; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:18.912Z; registry revision: 2026-10-16 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Psilocybin
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive DisorderNCT07227454RecruitingPhase 3Source start: 2026-01-08 (actual)
Source date details

Start: 2026-01-08 (precision: day; source type: ACTUAL; actual)

Primary completion: 2031-04-09 (precision: day; source type: ESTIMATED; estimated)

Study completion: 2031-09-15 (precision: day; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:18.160Z; registry revision: 2026-09-25 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Ketamine
Comparative Effectiveness of ECT vs. KETAMINE Over the LifespanNCT06034821Enrolling by invitationPhase 4Source start: 2023-10-01 (actual)
Source date details

Start: 2023-10-01 (precision: day; source type: ACTUAL; actual)

Primary completion: 2030-10-01 (precision: day; source type: ESTIMATED; estimated)

Study completion: 2030-12-01 (precision: day; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:17.019Z; registry revision: 2025-12-15 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Ketamine
A Study of Psilocybin for Major Depressive Disorder (MDD)NCT03866174CompletedPhase 2Source start: 2020-01-23 (actual)
Saved start 2019-10-15 differs from reported 2020-01-23; the saved day is not established by this observation.
Source date details

Start: 2020-01-23 (precision: day; source type: ACTUAL; actual)

Primary completion: 2022-06-28 (precision: day; source type: ACTUAL; actual)

Study completion: 2022-06-28 (precision: day; source type: ACTUAL; actual)

Observation retrieved: 2026-10-31T20:06:14.687Z; registry revision: 2026-04-22 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Psilocybin
Ketamine for Treatment of MS FatigueNCT03500289CompletedPhase 1Source start: 2018-08-10 (actual)
Source date details

Start: 2018-08-10 (precision: day; source type: ACTUAL; actual)

Primary completion: 2019-08-30 (precision: day; source type: ACTUAL; actual)

Study completion: 2019-08-30 (precision: day; source type: ACTUAL; actual)

Observation retrieved: 2026-10-31T20:06:14.296Z; registry revision: 2020-08-18 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Ketamine

About this data

Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.

Substance hubs for these compounds

Psilocybin | Ketamine

Country hub: United States

All trial hubs | Learn | Disclaimer